Published in Lancet on November 04, 2000
Shrinking the malaria map: progress and prospects. Lancet (2010) 8.21
Operational strategies to achieve and maintain malaria elimination. Lancet (2010) 6.48
The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
A research agenda for malaria eradication: drugs. PLoS Med (2011) 3.90
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med (2010) 3.78
Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med (2013) 3.23
The use of mobile phone data for the estimation of the travel patterns and imported Plasmodium falciparum rates among Zanzibar residents. Malar J (2009) 2.89
Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J (2010) 2.47
Community participation for malaria elimination in Tafea Province, Vanuatu: Part I. Maintaining motivation for prevention practices in the context of disappearing disease. Malar J (2010) 2.04
The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One (2011) 1.95
The architecture and effect of participation: a systematic review of community participation for communicable disease control and elimination. Implications for malaria elimination. Malar J (2011) 1.88
The changing limits and incidence of malaria in Africa: 1939-2009. Adv Parasitol (2012) 1.72
Malaria on isolated Melanesian islands prior to the initiation of malaria elimination activities. Malar J (2010) 1.62
Mass drug administration for malaria. Cochrane Database Syst Rev (2013) 1.54
The role of submicroscopic parasitemia in malaria transmission: what is the evidence? Trends Parasitol (2014) 1.50
A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis (2011) 1.49
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J (2011) 1.42
Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J (2013) 1.40
Baseline spatial distribution of malaria prior to an elimination programme in Vanuatu. Malar J (2010) 1.37
Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J (2012) 1.35
A sticky situation: the unexpected stability of malaria elimination. Philos Trans R Soc Lond B Biol Sci (2013) 1.32
Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg (2015) 1.28
Malaria elimination in Isabel Province, Solomon Islands: establishing a surveillance-response system to prevent introduction and reintroduction of malaria. Malar J (2011) 1.24
Population screening for glucose-6-phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. Malar J (2010) 1.23
Malaria vaccines and their potential role in the elimination of malaria. Malar J (2008) 1.21
A cluster randomized controlled cross-over bed net acceptability and preference trial in Solomon Islands: community participation in shaping policy for malaria elimination. Malar J (2009) 1.16
Community participation for malaria elimination in Tafea Province, Vanuatu: part II. Social and cultural aspects of treatment-seeking behaviour. Malar J (2011) 1.15
Malaria transmission pattern resilience to climatic variability is mediated by insecticide-treated nets. Malar J (2008) 1.14
A second chance to tackle African malaria vector mosquitoes that avoid houses and don't take drugs. Am J Trop Med Hyg (2013) 1.11
Malaria and its possible control on the island of Príncipe. Malar J (2003) 1.11
A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J (2014) 1.11
Push by a net, pull by a cow: can zooprophylaxis enhance the impact of insecticide treated bed nets on malaria control? Parasit Vectors (2014) 1.06
Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Malar J (2010) 1.06
Regime shifts and heterogeneous trends in malaria time series from Western Kenya Highlands. Parasitology (2012) 1.05
Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malar J (2013) 1.05
The failure of screening and treating as a malaria elimination strategy. PLoS Med (2014) 1.02
Suppressive effect of azithromycin on Plasmodium berghei mosquito stage development and apicoplast replication. Malar J (2010) 1.00
When they don't bite, we smell money: understanding malaria bednet misuse. Parasitology (2013) 0.99
Behavioral risk factors for obesity during health transition in Vanuatu, South Pacific. Obesity (Silver Spring) (2013) 0.94
Characteristic age distribution of Plasmodium vivax infections after malaria elimination on Aneityum Island, Vanuatu. Infect Immun (2013) 0.92
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission. Cochrane Database Syst Rev (2014) 0.91
Larvivorous fish for preventing malaria transmission. Cochrane Database Syst Rev (2013) 0.91
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev (2015) 0.90
Interrupting malaria transmission: quantifying the impact of interventions in regions of low to moderate transmission. PLoS One (2010) 0.90
Determinants of the use of insecticide-treated bed nets on islands of pre- and post-malaria elimination: an application of the health belief model in Vanuatu. Malar J (2014) 0.85
A prescription for sustaining community engagement in malaria elimination on Aneityum Island, Vanuatu: an application of Health Empowerment Theory. Malar J (2015) 0.83
The acceptability of mass administrations of anti-malarial drugs as part of targeted malaria elimination in villages along the Thai-Myanmar border. Malar J (2016) 0.82
Prevention of Malaria Resurgence in Greece through the Association of Mass Drug Administration (MDA) to Immigrants from Malaria-Endemic Regions and Standard Control Measures. PLoS Negl Trop Dis (2015) 0.81
The Utility of Malaria Rapid Diagnostic Tests as a Tool in Enhanced Surveillance for Malaria Elimination in Vanuatu. PLoS One (2016) 0.80
High and Heterogeneous Prevalence of Asymptomatic and Sub-microscopic Malaria Infections on Islands in Lake Victoria, Kenya. Sci Rep (2016) 0.80
Diversity of Plasmodium falciparum chloroquine resistance transporter (pfcrt) exon 2 haplotypes in the Pacific from 1959 to 1979. PLoS One (2012) 0.80
Plasmodium vivax and Plasmodium falciparum at the crossroads of exchange among islands in Vanuatu: implications for malaria elimination strategies. PLoS One (2015) 0.79
Transmission of malaria and genotypic variability of Plasmodium falciparum on the island of Annobon (Equatorial Guinea). Malar J (2007) 0.79
Reimagining malaria: five reasons to strengthen community engagement in the lead up to malaria elimination. Malar J (2015) 0.78
Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis (2016) 0.77
Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malar J (2016) 0.77
Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit Vectors (2017) 0.75
Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. Malar J (2017) 0.75
Malaria eradication on islands. Lancet (2001) 0.75
Low prevalence of Plasmodium and absence of malaria transmission in Conakry, Guinea: prospects for elimination. Malar J (2016) 0.75
Population- and individual-specific regulatory variation in Sardinia. Nat Genet (2017) 0.75
The economics of malaria control and elimination: a systematic review. Malar J (2016) 0.75
Application of loop analysis for evaluation of malaria control interventions. Malar J (2014) 0.75
A stochastic model for the probability of malaria extinction by mass drug administration. Malar J (2017) 0.75
Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med (1984) 3.49
Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci U S A (1984) 2.52
Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg (2001) 2.34
Chloroquine-resistant falciparum malaria in Madagascar and Kenya. Ann Trop Med Parasitol (1981) 2.03
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90
Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis (1999) 1.81
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop (2003) 1.80
Fever episodes in a holoendemic malaria area of Tanzania: parasitological and clinical findings and diagnostic aspects related to malaria. Trans R Soc Trop Med Hyg (1993) 1.79
Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest (1996) 1.74
Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev (1989) 1.73
Agranulocytosis associated with malaria prophylaxis with Maloprim. Br Med J (Clin Res Ed) (1983) 1.72
Autoimmune response to DNA, red blood cells, and thymocyte antigens in association with polyclonal antibody synthesis during experimental African trypanosomiasis. J Immunol (1979) 1.60
Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther (2005) 1.59
Malaria chemoprophylaxis with mefloquine. Lancet (1991) 1.55
Characterization of the humoral immune response in Plasmodium falciparum malaria. I. Estimation of antibodies to P. falciparum or human erythrocytes by means of microELISA. Clin Exp Immunol (1983) 1.54
Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci U S A (1986) 1.51
Malaria prophylaxis policy for travellers from Europe to the Indian Subcontinent. Malar J (2006) 1.42
Anti-Plasmodium falciparum antibodies acquired by residents in a holoendemic area of Liberia during development of clinical immunity. Am J Trop Med Hyg (1986) 1.40
Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol (1996) 1.35
Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction. Trans R Soc Trop Med Hyg (1999) 1.34
On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther (1983) 1.34
Pneumocystis carinii pneumonia: detection of parasites in sputum and bronchoalveolar lavage fluid by monoclonal antibodies. BMJ (1988) 1.34
Synergism of benflumetol and artemether in Plasmodium falciparum. Am J Trop Med Hyg (1999) 1.33
Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol (1984) 1.32
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ (2003) 1.31
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal (2007) 1.27
The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol (2005) 1.25
A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and beta-thalassaemia traits. Ann Trop Med Parasitol (1983) 1.24
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.24
In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1991) 1.21
Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop (2006) 1.19
Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop (1998) 1.19
Different malaria control activities in an area of Liberia--effects on malariometric parameters. Ann Trop Med Parasitol (1985) 1.19
Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol (2004) 1.18
Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct gammadelta+ T cell patterns in Plasmodium falciparum and P. vivax infections. Clin Exp Immunol (1997) 1.14
Falciparum malaria and beta-thalassaemia trait in northern Liberia. Ann Trop Med Parasitol (1983) 1.14
Long-term survival in transfusion recipients in Sweden, 1993. Transfusion (2001) 1.12
Human monoclonal antibodies to Pf 155, a major antigen of malaria parasite Plasmodium falciparum. Science (1986) 1.11
Differences in perception of everyday odors: a Japanese-German cross-cultural study. Chem Senses (1998) 1.10
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics (1999) 1.09
Perception of everyday odors--correlation between intensity, familiarity and strength of hedonic judgement. Chem Senses (1999) 1.07
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. Ann Trop Med Parasitol (2002) 1.06
Characterization of the humoral immune response in Plasmodium falciparum malaria. III. Factors influencing the coexpression of antibody isotypes (IgM and IgG-1 to 4). Clin Exp Immunol (1986) 1.05
Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia. Trans R Soc Trop Med Hyg (1999) 1.05
Acute psychosis following mefloquine prophylaxis. Lancet (1989) 1.05
Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS (1999) 1.05
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother (2002) 1.04
Higher proportion of CD8+ T cells in the blood in healthy adults from Ethiopia and Bangladesh compared with Sweden. Trans R Soc Trop Med Hyg (1998) 1.04
pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother (2012) 1.04
T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci U S A (1988) 1.03
Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull World Health Organ (1989) 1.03
In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol (1986) 1.03
Functional MRI detection of activation in the primary gustatory cortices in humans. Chem Senses (2005) 1.02
Induction of thymocytotoxic autoantibodies after injection of bacterial lipopolysaccharides in mice. Eur J Immunol (1979) 1.00
Lack of effect of desipramine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. Trans R Soc Trop Med Hyg (1992) 1.00
Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. Trop Med Int Health (1997) 0.99
Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J Chromatogr (1986) 0.98
Micronutrient and iron supplementation and effective antimalarial treatment synergistically improve childhood anaemia. Trop Med Int Health (2000) 0.98
Evaluation of three qualitative tests for detection of chloroquine in urine--agreement with plasma concentrations determined with liquid chromatography. Ann Trop Med Parasitol (1986) 0.98
Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol (1998) 0.98
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics (1999) 0.97
Reliability of Dill-Glazko test. Lancet (1985) 0.97
Human monocytes cultured with and without interferon-gamma inhibit Plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. Parasite Immunol (1994) 0.97
High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet (1997) 0.97
A study on malaria infection during the acute stage of measles infection. J Trop Med Hyg (1991) 0.97
Regulation of the immune response in Plasmodium falciparum malaria: IV. T cell dependent production of immunoglobulin and anti-P. falciparum antibodies in vitro. Clin Exp Immunol (1987) 0.96
A longitudinal study of antibodies to the Plasmodium falciparum antigen Pf155/RESA and immunity to malaria infection in adult Liberians. Trans R Soc Trop Med Hyg (1991) 0.96
The seroreactivity against Pf155 (RESA) antigen in villagers from a mesoendemic area in Somalia. Trop Med Parasitol (1989) 0.95
The effect of artemisinine, its derivatives and mefloquine against chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg (1992) 0.94
Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand J Infect Dis (1994) 0.94
Detection of asymptomatic Pneumocystis carinii infection by polymerase chain reaction: predictive for subsequent pneumonia. AIDS (1996) 0.93
Improved sensory relearning after nerve repair induced by selective temporary anaesthesia - a new concept in hand rehabilitation. J Hand Surg Br (2005) 0.93
The working capacity of Liberian males: a comparison between urban and rural populations in relation to malaria. Ann Trop Med Parasitol (1981) 0.92
Functional outcome thirty years after median and ulnar nerve repair in childhood and adolescence. J Bone Joint Surg Am (2013) 0.92
Immune response against protozoal and nematodal infection in mice with underlying Schistosoma mansoni infection. Parasitol Int (1999) 0.91
A Plasmodium falciparum antigen containing clusters of asparagine residues. Proc Natl Acad Sci U S A (1986) 0.91
Field study of cyproheptadine/chloroquine synergism in falciparum malaria. Lancet (1990) 0.91
Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp Parasitol (2002) 0.91
No evidence of nosocomial Pneumocystis carinii infection via health care personnel. Scand J Infect Dis (1997) 0.90
Diagnosis of Plasmodium falciparum infection by spot hybridization assay: specificity, sensitivity, and field applicability. Bull World Health Organ (1986) 0.90
Thymocytotoxic autoantibodies found in mice infected with Schistosoma japonicum. Infect Immun (1981) 0.89
Pneumocystis carinii is not a major cause of pneumonia in HIV infected patients in Lusaka, Zambia. Trans R Soc Trop Med Hyg (1990) 0.89
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol (2008) 0.89
Genetic diversity and gene flow of humans, Plasmodium falciparum, and Anopheles farauti s.s. of Vanuatu: inferred malaria dispersal and implications for malaria control. Acta Trop (2007) 0.88
Monthly antimalarial chemotherapy to children in a holoendemic area of Liberia. Ann Trop Med Parasitol (1986) 0.88
The protective effect of tinoridine against carbon tetrachloride hepatotoxicity. Toxicol Appl Pharmacol (1980) 0.87
Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics. Acta Trop (1997) 0.87